Emglif™

Therapeutic Segment:
Anti-diabetic

Generic Name:
Empagliflozin

Description:
Emglif tablets contain Empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Each film-coated tablet of Emglif contains 10mg or 25mg of Empagliflozin (free base).

Indication:
Emglif is indicated:  As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Limitations of Use: Emglif is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Formulation:

• Tablets

Strength:

• 10mg
• 25mg

Pack Size:

• 28’s
• 14’s